Stock ASTRAZEN ASTRAZENECA PHARMA INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials AstraZeneca Pharma India Limited

Equities

ASTRAZEN

INE203A01020

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:50 2024-04-26 am EDT 		5-day change 1st Jan Change
5,415 INR +1.53% Intraday chart for AstraZeneca Pharma India Limited +4.70% -1.89%
Apr. 08 AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director CI
Mar. 25 AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024 CI

Valuation

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Capitalization 1 23,162 49,958 59,789 75,255 63,886 81,182
Enterprise Value (EV) 1 21,906 48,225 57,382 71,853 59,488 76,251
P/E ratio 89.4 x 91.7 x 82.8 x 80.7 x 104 x 81.8 x
Yield - - 0.04% 0.07% 0.39% 0.49%
Capitalization / Revenue 4.06 x 6.86 x 7.19 x 9.25 x 7.93 x 8.09 x
EV / Revenue 3.84 x 6.62 x 6.9 x 8.83 x 7.38 x 7.6 x
EV / EBITDA 44.8 x 67.5 x 48.6 x 54.2 x 72 x 47.3 x
EV / FCF -189 x 99.7 x 75.3 x 85.3 x 66 x 100 x
FCF Yield -0.53% 1% 1.33% 1.17% 1.52% 1%
Price to Book 9.38 x 16.6 x 16.4 x 16.5 x 12.5 x 13.8 x
Nbr of stocks (in thousands) 25,000 25,000 25,000 25,000 25,000 25,000
Reference price 2 926.5 1,998 2,392 3,010 2,555 3,247
Announcement Date 8/10/18 7/10/19 7/17/20 7/16/21 7/15/22 7/22/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 5,710 7,283 8,318 8,136 8,056 10,030
EBITDA 1 488.6 714.9 1,180 1,326 826.7 1,613
EBIT 1 341.2 565.7 1,026 1,163 693.6 1,489
Operating Margin 5.98% 7.77% 12.33% 14.29% 8.61% 14.84%
Earnings before Tax (EBT) 1 438 726.7 1,140 1,271 830.4 1,341
Net income 1 259.1 544.5 722.1 933 616 992.9
Net margin 4.54% 7.48% 8.68% 11.47% 7.65% 9.9%
EPS 2 10.36 21.78 28.88 37.32 24.64 39.72
Free Cash Flow 1 -116.2 483.5 762.5 841.9 901.3 762.4
FCF margin -2.03% 6.64% 9.17% 10.35% 11.19% 7.6%
FCF Conversion (EBITDA) - 67.63% 64.63% 63.48% 109.02% 47.26%
FCF Conversion (Net income) - 88.79% 105.59% 90.24% 146.31% 76.79%
Dividend per Share - - 1.000 2.000 10.00 16.00
Announcement Date 8/10/18 7/10/19 7/17/20 7/16/21 7/15/22 7/22/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,257 1,732 2,407 3,402 4,398 4,931
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -116 483 762 842 901 762
ROE (net income / shareholders' equity) 11% 19.9% 21.7% 22.7% 12.7% 18.1%
ROA (Net income/ Total Assets) 4.87% 6.92% 10.1% 9.81% 5.31% 10.1%
Assets 1 5,322 7,872 7,143 9,509 11,590 9,826
Book Value Per Share 2 98.80 120.0 146.0 182.0 205.0 235.0
Cash Flow per Share 2 45.60 69.30 33.40 141.0 179.0 200.0
Capex 1 62.8 187 142 77.1 96.2 85.2
Capex / Sales 1.1% 2.57% 1.71% 0.95% 1.19% 0.85%
Announcement Date 8/10/18 7/10/19 7/17/20 7/16/21 7/15/22 7/22/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ASTRAZENECA PHARMA INDIA LIMITED Stock AstraZeneca Pharma India Limited
-1.89% 1.62B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ASTRAZEN Stock
  4. Financials AstraZeneca Pharma India Limited